EONOMYNEXT – Sri Lanka’s cabinet of ministers has approved a proposal to purchase the Denosumab injection, a drug used for cancer treatments from Medmart Pharma (Pvt.) Ltd
Some 32,000 vials of 100mg/4ml of Denosumab are to be purchased at a cost of Rs 220.8 million, the cabinet office said in a statement.
Denosumab is a monoclonal antibody that works as a RANK ligand (RANKL) inhibitor. This medication is classified as a “bone-modifying agent”.
Prolia or Xgeva is the trade name of Denosumab. Prolia and Xgeva are the same generic drug but they were given distinct trade names in order to differentiate between their unique dosing schedules and indications for use, reports show.
Prolia is used to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
Xgeva is used for the prevention of skeletal-related events (need for radiation, fracture due to cancer in the bone, surgery to the bone, or compression of the spinal cord) in patients with multiple myeloma and bone metastases from solid tumors and treatment of giant cell tumor of the bone. (Colombo/June01/2021)